Israel Englander C4 Therapeutics, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 1,101,342 shares of CCCC stock, worth $2.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,101,342

Previous 65,897 1571.31%

Holding current value

$2.47 Million

Previous $105,000 1399.05%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.1 - $1.74 $1.14 Million - $1.8 Million	1,035,445 Added 1571.31%	1,101,342 $1.57 Million
Q1 2025 May 15, 2025	SELL	$1.6 - $4.09 $470,764 - $1.2 Million	-294,228 Reduced 81.7%	65,897 $105,000
Q4 2024 Feb 14, 2025	BUY	$3.6 - $7.0 $1.22 Million - $2.37 Million	338,277 Added 1548.32%	360,125 $1.3 Million
Q3 2024 Nov 14, 2024	SELL	$4.43 - $7.38 $2.16 Million - $3.6 Million	-487,558 Reduced 95.71%	21,848 $124,000
Q2 2024 Aug 14, 2024	SELL	$4.05 - $8.1 $266,186 - $532,372	-65,725 Reduced 11.43%	509,406 $2.35 Million
Q1 2024 May 15, 2024	SELL	$5.3 - $11.0 $832,174 - $1.73 Million	-157,014 Reduced 21.45%	575,131 $4.7 Million
Q4 2023 Feb 14, 2024	SELL	$1.18 - $6.03 $1.66 Million - $8.46 Million	-1,403,452 Reduced 65.72%	732,145 $4.14 Million
Q2 2023 Aug 14, 2023	BUY	$2.75 - $3.77 $5.45 Million - $7.47 Million	1,982,041 Added 1290.76%	2,135,597 $5.87 Million
Q1 2023 May 15, 2023	BUY	$3.1 - $9.02 $476,023 - $1.39 Million	153,556 New	153,556 $482,000

Others Institutions Holding CCCC

# of Institutions

104

Shares Held

57.2M

Call Options Held

15.2K

Put Options Held

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $110M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account